# Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB

> **NCT04187469** · NA · UNKNOWN · sponsor: **Fifth Affiliated Hospital, Sun Yat-Sen University** · enrollment: 286 (estimated)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Moxifloxacin, Isoniazid, Rifampicin
- **DRUG:** Rifampicin,Isoniazid,Pyrazinamide,Ethambutol

## Key facts

- **NCT ID:** NCT04187469
- **Lead sponsor:** Fifth Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2023-02-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2019-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04187469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04187469, "Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04187469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*